Clinical efficacy and safety of thalidomide combined with CHOP regiment in the treatment of aggressive non-hodgkin′s lymphoma
10.13699/j.cnki.1001-6821.2015.16.009
- VernacularTitle:沙利度胺联合 CHOP 方案治疗侵袭性非霍奇金淋巴瘤的临床疗效及安全性评价
- Author:
Xiao-Qiu WANG
1
;
Bing-Mu FANG
;
Jin-Hong JIANG
;
Zhi-Gang QU
;
Yong-Hua LIU
;
Guang-Li MA
;
Kang YU
Author Information
1. 温州医科大学 附属第六医院 血液科
- Keywords:
aggressive non -hodgkin′s lymphoma;
CHOP regiment;
thalidomide;
clinical effect;
chemotherapy related side effect
- From:
The Chinese Journal of Clinical Pharmacology
2015;(16):1588-1590
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of CHOP chemotherapy regiment combined with thalidomide in the treatment of aggressive non-hodgkin′s lymphoma.Methods Seventy-two cases of aggressive non-hodgkin′s lymphoma were recruited in this study and randomly divided into control group ( n =35 ) and treatment group (n=37). Patients in the control were given CHOP chemotherapy ( cyclophosphamide 600 mg ? m-2 intravenous injection, day 1+epirubicin 40 mg? m-2 ntravenous injection, day 1+vinblastine 1.4 mg? m-2 ntravenous injection, day 1+dehydrocortisone 50 mg? m-2 , orally, day 1-7).Patients in the treatment group were given CHOP chemotherapy regiment combined with thalidomide ( thalidomide 200 mg, day 1 -14, orally, at the second phrase thalidomide 400 mg, day 1-14).After 4 cycles treatment, the objective response rate, 1 and 2 year survival rate and chemotherapy associated toxicity were assessed between the two groups. Results The objective response rate were 78.38% and 57.14% in the treatment and control group respectively with the treatment group statistical higher than control group( P<0.05). The 1 and 2 years survival rate were 65.71%and 40.00%in the control group which was significant lower than that in the treatment group(1 and 2 years survival rate 81.08%, 62.16%, P<0.05) .The chemotherapy associated toxicity such as granulopenia, nausea and vomiting, alopecie and et al had no statistical difference between the two groups (P>0.05).Conclusion CHOP chemotherapy regiment combined with thalidomide can improve the objective response rate without increasing the toxicity in treatment of aggressive non-hodgkin′s lymphoma.
